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Introduction
Intrahepatic cholangiocarcinoma (ICC) is a devastating 
malignancy of the biliary tree which is notoriously difficult 
to diagnose (1). Survival remains at less than 12 months 
after diagnosis due to clinical latency, lack of effective non-
surgical therapies and aggressive tumors (1-4). Surgical 
resection is the only chance of cure, but in up to 70% of 
cases ICC is unresectable (5-8). Systemic chemotherapy and 
radiotherapy as primary, adjuvant or palliative treatments 
have poor response rates and are limited by systemic 
toxicities (9-14).
Since 1980, TAE has become available for targeted 
treatment of both primary and secondary hepatic 
malignancies (15). The common modalities for TAE are 
bland embolization, trans-arterial chemoembolization 
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(TACE) or chemoinfusion (TACI), and selective internal 
radiation therapy (SIRT). These are performed via the 
hepatic artery and allow selective delivery of anti-tumor 
agents or radioactive microspheres. This targeted approach 
minimizes systemic toxicity or exposure of healthy tissue to 
radiation. 
TACE and TACI have shown to improve median 
survival by 2-7 months compared to systemic therapies (16). 
Several observational studies on SIRT have also reported 
similar benefits on overall survival and tumor response rates 
of up to 86% (17-19). In the context of inoperability and 
increasing evidence of survival benefit conferred by trans-
arterial approach, such therapies have become important 
and widely used treatment options. However, systematic 
evaluation of data for each treatment modality remains 
limited. 
This  study reviews the ef fect  of  trans-arteria l 
emoblisation therapies for unresectable ICC. Primary 
outcomes were response and survival outcomes. Secondary 
outcomes were treatment complications and prognostic 
factors for overall survival.
Methods
The structure of this systematic review followed the 
PRISMA guidelines (20).
Definition of treatment modalities
TACE delivers high doses of chemotherapy directly to the 
cancer cells via the hepatic artery. Additionally, embolic 
agents are injected to reduce arterial inflow and increase 
bioavailability of the drugs (21). Bland embolization is 
another form of TACE that uses particles and/or embolic 
agents to block blood flow to the tumor without the use 
of chemotherapeutic agents. Another alternative includes 
the use of drug-eluting beads embedded with irinotecan 
(DEBTACE).
TACI is a catheter-based therapy using an arterial port 
in the hepatic artery. Its delivery of chemotherapeutic drugs 
is similar to TACE, but embolization is not used in TACE. 
TACI maximizes targeted drug delivery by selective vessel 
catheterization (5).
SIRT delivers internal radiation selectively to the tumor 
bed. Yttrium-90 (Y90) is impregnated in glass or resin-
based microspheres (5). The type, size and number of 
microspheres per treatment varies (22).
Eligibility criteria
Studies considered for review had the following pre-
determined inclusion criteria: (I) adult patients with 
primary ICC; (II) unresectable, chemorefractory or failed 
previous surgical resection; (III) TAE as the treatment 
modality; and (IV) clinical outcomes and complications 
assessed and reported. Resectibility is assessed using 
patient and disease factors including comorbidities, fitness 
for surgery and tumor location and size (23). A tumor is 
deemed unresectable if clear margins cannot be achieved by 
resection and there are evidence of metastases (24,25).
These studies were restricted according to the following 
report characteristics: (I) publication date after January 
2000; (II) English language; and (III) original research. The 
search period was restricted to be more representative of 
modern post-operative outcomes.
Information sources and search strategy
On December 2013, a literature search was conducted 
using MeSH keyword search on PubMed (MEDLINE) 
for all studies which matched the eligibility criteria 
above (Figure 1). An additional manual search of OVID 
(MEDLINE) and EBSCOhost (EMBASE) as well as 
bibliographies of each included study was conducted to 
identify studies not covered by the initial MeSH keyword 
search. All identified articles were retrieved from the 
aforementioned databases.
Study selection
Following the search, two reviewers independently 
performed screening of titles and abstracts after MeSH 
keyword and manual searches. Studies were excluded if 
they did not meet eligibility criteria. Consensus for studies 
included for review was achieved by discussion between 
reviewers based on the pre-determined eligibility criteria.
Studies were classified into levels of evidence using the 
National Health and Medical Research Council evidence 
hierarchy (42).
Data items and extraction
All data items for assessment of study quality (Table 1) and 
study results (Table 2) were pre-determined. Data extraction 
was then performed by two independent reviewers using 
a standardised protocol. Data extracted include the 
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methodology, quality appraisal, patient characteristics, 
treatment toxicity, radiological response, overall survival, 
progression-free survival and prognostic factors. Overall 
survival and progression-free survival were determined from 
the time of TAE.
Synthesis of results
Data was synthesized by qualitative and quantitative 
review based on the outcomes criteria and data extracted 
in tables as outlined above. Statistical data are presented 
as percentages or median (range). A meta-analysis was not 
performed due to the following reasons: (I) heterogeneous 
data prevented complete meta-analysis; some studies had 
no reference population and others compared trans-arterial 
therapy with surgery or systemic chemotherapy; (II) statistical 
limitations due to missing data or inconsistencies in data 
presentation and (III) methodological inconsistencies such 
as varied follow-up time points for survival rates.
Risk of bias
The risk of bias in individual studies was assessed by a 
qualitative analysis based on study quality and data tabulated 
in Table 1.
Results
Study selection
After careful systematic selection, 20 studies were selected 
for review (17-19,23,26-41). Full details of the search 
algorithm are outlined in Figure 1.
Study characteristics and risk of bias within studies (Table 1)
The sample size ranged between 9 to 198. Only four studies 
included greater than 50 patients (30-32,38). The number 
of patients in most studies is low and this is a significant 
source of bias. 
S e v e n  s t u d i e s  u s e d  r a d i o e m b o l i z a t i o n  ( 1 7 -
19,26,27,38,39). Hyder et al. compared TACE, DEBTACE 
and traditional SIRT (38). TACI was assessed in two 
studies (36,41). One study compared TACE with systemic 
chemotherapy (29) and nine studies assessed TACE with no 
comparators (23,28,30-33,35,37,40).
Heterogeneous patient demographics, tumor type and 
pathology, and treatment combinations in included studies 
resulted in a wide range of results derived from each 
article (Tables 1,2). This discrepancy reflects the lack of 
standardized protocol for trans-arterial therapies to facilitate 
consistent patient selection and treatment regimens. These 
therapies are relatively new, and although their efficacy has 
been reported in multiple studies, a summary of evidence is 
required.
Study design limited the strength of evidence of included 
articles. Twelve studies were retrospective (19,26,28-
30,32,33,35-38,41) and no randomized controlled trial 
was present in this review. Both are potential sources of 
bias. The reasons for the lack of randomized studies may 
be multifactorial. In the context of known survival benefit 
conferred by trans-arterial therapies, it may be unethical to 
deny patients trans-arterial therapies. 
All studies had level of evidence II and III. The results of 
studies were similar between lower (19,26,28-30,32,33,35-
38,41) and higher level (17,18,23,27,31,34,39,40) evidence 
articles which demonstrates good consistency of results 
across studies. 
Figure 1 Search algorithm (17-19,23,26-41). #, eligibility 
criteria outlined in methods section: (I) adult patients with 
primary intrahepatic cholangiocarcinoma; (II) unresectable, 
chemorefractory or failed previous surgical resection; (III) patients 
received transarterial chemoembolization, chemoinfusion, and/
or radioembolization; (IV) assessment of clinical outcomes and 
complications; (V) original research.
20 articles included (17-19,23,26-41)
Being appropriate for this review due to relevancy 
to this topic and scientific accuracy of the 
reported results
Plus manual search EMBASE, MEDLINE, 
EBSCO databases and bibliographies of 
all included studies 5 articles (18,38-41)
Search algorithm
31/12/2013
“cholangiocarcinoma” [MeSH Terms] 
AND “embolization, therapeutic” 
[MeSH Terms] AND “unresectable” 
[Text word] AND English [Language] 
AND (“2000” [PDAT] “3000” [PDAT]
30 articles identified
Did not meet eligibility 
criteria# 15 articles excluded
15 articles selected (17,19,23,26-37)
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Patient characteristics (Table 2)
The median age at the time of each study was between 
56 and 68. The mean follow-up period was 13.7 (1.9-29) 
months. 
The majority of patients had bilobar disease 59.5% (24-
77%). Extra-hepatic metastases were present in 35% (12-
85%) of patients with 35% (27-100%) of patients having 
received previous chemotherapy. Prior liver resection 
was undertaken in 11.6% (11-40%) of patients. Post-
procedure chemotherapy was administered in eight studies 
(17,28,33,35,36,38,40,41).
Assessment of outcomes (Table 3)
Follow-up occurred for 13.3 [8-29] months after therapy 
and radiological tumor response was recorded using 
Response Evaluation Criteria In Solid Tumors (RECIST) 
in all studies. The average reported RECIST value for 
complete and partial response (PR) was 6% (0-35%) 
and 22.4% (7-90%), respectively. The time to tumor 
progression was 8.2 (1.8-10) months with a median overall 
survival of 13 (9.1-30) months amongst all treatment 
modalities. Median overall survival in studies using 
radioembolization was 12.5 months and in studies using 
chemoembolization was 13 months. Overall 1-year survival 
for all treatments was 53.5 [40-78] months [median: SIRT 
54.5% (40-61%), TACE 53% (38-78%)].
Treatment toxicity (Table 4)
Table 4 summarizes adverse effects associated with trans-
arterial therapies. Side effects related to post-embolization 
syndrome in several studies occurred within the first few 
days of treatment (27,31,36,40). Other complications were 
reported within 30 days of treatment. Delayed toxicity was 
not reported. The overall rate of acute toxicity was 34.9% 
(26.2-89%). Twelve studies graded the severity of toxicities 
(17-19,23,27,31,32,35,38-41). Of those who experienced 
treatment toxicities, 64.3% (38-79%) were considered mild 
and resolved without intervention (31,35,39,40).
The most frequent clinical toxicities were abdominal 
pain 40% (4-100%), nausea and vomiting 27% (6.1-
95%), and fatigue 19% (0-75%) (17-19,26,27,34,37). The 
incidence of gastroduodenal ulcers was 3% (0-20%) and 
did not require invasive treatment (17,18,26,27,32,37). 
Only one study by Shitara et al. reported 5% of perforated 
duodenal ulcer resulting in discontinuation of therapy (41). 
Serological toxicities included hematological abnormalities 
and deranged liver function test (LFT) results. Other 
complications reported were hepatic abscesses, acute 
myocardial infarction (AMI) and pulmonary embolism. 
Importantly, there were no deaths due to treatment 
toxicities. 
Prognostic factors (Table 5)
Increased multiplicity, localization and vascularity of the 
tumor were identified as factors associated with poor overall 
survival (17,26,30,35,43). Whilst multiple and infiltrating 
tumor was a negative prognostic factor for SIRT, Mouli, 
2013 #114; Saxena, 2010 #35; Hoffmann, 2012 #21 
hypovascularity of the tumor was associated with poor 
outcome with TACE (30,43). Worse performance status 
as measured by Eastern Cooperative Oncology Group 
(ECOG) scale was a significant prognostic factor in studies 
assessing SIRT but not in those with chemotherapy-based 
treatments (17-19). Data on prognostic factors was scarce 
and there was inconsistency across the studies.
Discussion
Summary of evidence and interpretation
The ideal approach to treatment of inoperable disease is 
poorly defined. TAE therapies are a novel and increasingly 
performed approach for treating unresectable ICC. 
Outcomes are promising, but there is no standardized 
protocol for treatment regime, combination of agents and 
patient selection. Studies have examined clinical outcomes 
of various chemotherapeutic and radioactive agents, on 
their own or in combinations, but with inconsistent results 
(29,30,35). Combination treatment of TACE and TACI 
has also been reported (23,43). A potential alternative to 
Y90 radioembolization is DEBTACE. Four studies in this 
review have compared this treatment with conventional 
TAE therapies (29,34,38,40).
Patient characteristics of the studies summarized in this 
review confirm that trans-arterial therapies are offered to 
a variety of patients with incurable disease. A significant 
proportion of patients in this review had advanced disease 
with bilobar tumors and extra-hepatic metastases. About 
35% to 100% of patients received chemotherapy prior to 
trans-arterial treatment. In 10% to 40% of patients, hepatic 
resection had already been performed. The survival benefit 
achieved by trans-arterial therapies across a variety of 
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Table 5 Clinical and pathological factors associated with poorer overall survival on univariate analysis
Factors
Association with poorer overall survival
Significant Non-significant
Tumor type (infiltrating vs. peripheral) aMouli (26), aSaxena (17), Gusani (35): 3 studies Vogl (30), Kim (36): 2 studies
ECOG aHoffman (19) (0 vs. 1,2), aSaxena (17) (0 vs. ≥1), 
aIbrahim (0 vs. 1,2) (18): 3 studies
Park (32): 1 study
Number of lesions (multifocal) aMouli (26): 1 study Vogl (30): 1 study
Location of lesions Park (32), Kim (36)
Tumor burden aHoffman (19): 1 study Park (32): 1 study
Tumor hypovascularity Kim (36), Vogl (30): 2 studies Park (32): 1 study
Extra-hepatic disease Park (32): 1 study Kiefer (31): 1 study
RECIST aHoffman (19) (partial response P<0.001), Gusani (35), 
Park (32), Vogl (stable disease P<0.001) (30): 4 studies
TACE regime Gusani (35) [gemcitabine-cisplatin vs. gemcitabine 
alone (13.8 vs. 6.3 months, P=0.0005]: 1 study
Vogl (30): 1 study
Treatment regimes
TACE vs. TACI vs. TACE + TACI Kim (TACI alone P<0.001) (36): 1 study
TACE + DEBTACE vs. TACE or 
systemic chemotherapy
Kuhlmann (29): 1 study
Child pugh class (B vs. A) Vogl (Child Pugh B) (30): 1 study Kim (36): 1 study
Previous chemotherapy aHoffman (19): 1 study
Previous surgery aHoffman (19): 1 study
Portal vein thrombosis aIbrahim (18): 1 study
a, SIRT. AMI, acute myocardial infarction; APE, acute pulmonary edema; CTx, systemic chemotherapy; ECOG, Eastern 
Cooperative Oncology Group Performance Status; DEBTACE, irinotecan drug eluting beads; LFT, liver function test; NA, not 
applicable; NR, not reported; SIRT, selective internal radiation therapy; TACE, trans-arterial chemoembolization; TACI, trans-
arterial chemoinfusion.
patient groups shows these treatments are highly effective. 
However, the inconsistencies in patient demographics 
reflect the lack of specific patient selection criteria for trans-
arterial therapies and results should be interpreted in the 
context of this potential bias.
Our review showed that TACE, TACI and SIRT 
achieved similar rates of tumor response in unresectable 
ICC (Table 3). Seven studies used radioembolization (17-
19,26,27,38,39). Although none of these studies reported 
complete tumor response, rates for partial and stable 
response (SR) were higher than the average value reported 
by studies using chemoembolization. Overall and 1-year 
survival rates were also similar between the chemotherapy-
based and radiotherapy-based approaches. Median overall 
survival was 13 months. This is higher than median overall 
survival of 11 months for systemic chemotherapy, reported 
in the recent metaanalysis (11). In two studies, tumor 
reduction following trans-arterial therapy allowed surgical 
resection of the tumor (23,40). Surgical resection following 
trans-arterial therapy allows the possibility of cure for 
previously unresectable ICC.
With advances in treatment techniques and clinical 
outcome, recent focus has shifted to maximizing clinical 
efficacy by using combination of trans-arterial approaches, 
drugs and radioactive agents. Combination of various 
chemoinfusion and TACE protocols was applied upon 
case-by-case assessments by Burger et al., who reported the 
highest overall survival of 30 months (23). However, their 
study was limited by a small sample size and absence of 
control groups. Another study by Kim et al. supports that 
combination therapy may enhance efficacy of TACI (36). 
Whilst TACI alone was a significant negative prognostic 
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factor for overall survival, concomitant TACI and TACE 
achieved similar clinical success toTACE alone (36). 
Kuhlmann et al. compared systemic chemotherapy, TACE 
and DEBTACE, and found that combination therapy with 
TACE and DEBTACE is superior to both TACE and 
systemic chemotherapy alone (29).
Chemotherapy agents used across 13 studies using 
TACE and/or TACI varied widely; drugs included 
cisplatin, doxorubicin, gemcitabine, 5-fluorouracil, 
irinotecan, mitomycin C and oxaliplatin. Results on the 
optimal drug combination are controversial. Gusani et al. 
stated combination therapy using gemcitabine/cisplatin/
oxaliplatin were most beneficial for overall survival (35), 
but another study found no significant differences among 
drug combinations (30). Overall survival of 23 and 21 months 
were demonstrated in studies using oxaliplatin (33) and 
mitomycin (37), respectively. However, a quantitative 
analysis is needed to assess its significance. 
There are many studies analyzing predictors of survival 
in resectable ICC (44,45), but data is limited on trans-
arterial treatment of inoperable disease. Identifying 
prognostic factors can optimize patient selection and 
improve treatment outcomes. Currently, patient selection 
criteria for trans-arterial therapies are unclear (17,36). 
Prognostic factors differed between chemo- and radio-
embolization. ECOG status prior to treatment (17,19), 
multiple or bilobar tumors (26) and greater tumor burden/
volume (19) were negatively associated with SIRT outcomes 
whereas hypovascularity of the tumor (30,36) and extra-
hepatic involvements (32) were predictors of poor prognosis 
with TACE. Poor Child Pugh Class at treatment was also 
associated with poorer outcomes after TACE (30). These 
observations may be related to the rationale behind the 
different trans-arterial approaches. TACE exploits the fact 
that tumor draws most of its blood supply from the hepatic 
artery; hypervascular tumor may allow greater drug delivery 
and hence higher drug concentration (5). However, in light 
of the overall benefits of TAE and inadequate evidence, 
patients with hypovascular tumour should not be denied 
therapy until more evidence is acquired (36). SIRT delivers 
radioactive particles selectively and deeply within the 
tumor bed, hence greater tumor volume and multiplicity 
may require higher radiation doses and wider range of 
exposure risking unwanted toxicity (5). Assessment of tumor 
vascularity in TACE and measurement of tumor burden 
may identify ideal treatment options for patients with 
unresectable ICC. 
TAE is safe with mild to moderate toxicity. Overall 
30-day mortality in this study was 0.6% which is consistent 
with the most  recent  rate  of  0 .7% reported in  a 
meta-analysis (16). Studies in our review reported acute 
toxicity rate of 34.9%. The majority of post-procedural 
complications was within 30 days and resolved without 
intervention. The most common types of adverse effects 
in both chemo- and radio-embolization were abdominal 
pain, nausea and vomiting and fatigue. Mild to moderate 
gastrointestinal  ulcers and derangements in l iver 
function were also relatively common. Haematological 
complications were more prevalent following TACE and 
systemic chemotherapy (CTx). Hepatic abscesses were also 
only observed in patients undergoing TACE (34,35,46). 
This may be confounded by the higher prevalence of 
hematological toxicities including neutropenia. Although 
the trans-arterial approach allows more targeted delivery 
of drugs and radiation without unwanted toxic exposure, a 
degree of systemic toxicity may be inevitable. Nonetheless, 
delayed toxicity was not recorded in any of the studies 
and acute complications were mostly mild and resolved 
spontaneously. The reporting of adverse events was 
inconsistent between studies and not all studies graded 
treatment toxicity. There was also discrepancy in the acuity 
of complications. A standardized approach to assessment 
of adverse outcomes may be useful to allow more accurate 
comparisons of safety data.
Despite the growing evidence on the therapeutic 
potential of TAE, there is only one systematic review to date 
evaluating the safety and efficacy of only chemotherapy-
based treatments (16). However, in that study, no 
limitations in study design or publication dates were applied 
in their search, and the final selection of studies included 
abstracts for meetings and conferences. Although our study 
does not include a metaanalysis, we opted for meticulous 
selection of eligible studies using specific search criteria. In 
addition, meta-analysis of inappropriate and significantly 
heterogeneous data is not a necessary part of systematic 
reviews and the results of any metananalysis of such data 
should be interpreted with caution (47). To our knowledge, 
this is also the first review to assess all modalities of trans-
arterial therapy including radioembolization.
Review limitations
The main limitation of this study was that meta-analysis 
could not be performed due to statistical, methodological 
and clinical heterogeneity. In particular, the heterogeneity 
of patient demographics, tumor pathology and treatment 
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modality resulted in significant variation in results. Much of 
this is due to the lack of standardized treatment protocols. 
However, this review summarizes the best available evidence 
and provides useful information on the efficacy and safety of 
trans-arterial therapies for unresectable ICC.
Guidelines for future studies
This review demonstrates the lack of appropriate and 
consistent data required for meta-analysis. Prospective studies 
with pre-determined and standardized data assessment will 
be needed. This will facilitate consistent patient selection 
criteria and outcome measures providing appropriate volume 
and quality of data to accurately assess patient and disease 
characteristics and treatment outcomes including safety 
profile. There was no randomized controlled trial on trans-
arterial therapies identified by our search. Future randomized 
studies are required to assess efficacy of combined trans-
arterial therapies and the use of adjuvant systemic therapies 
in trans-arterial therapies. Specific drug combinations and 
therapy protocols need to be investigated further to assess 
the ideal treatment option for patients. 
Conclusions
Trans-arterial therapies are safe and effective treatment 
options for unresectable ICC. They confer improvement 
in overall survival and achieve tumor reduction, allowing 
curative surgical resection in some cases. Although no specific 
patient selection criteria or prognostic factors for treatment 
success exists, the results of this review suggest that there are 
various patient and disease factors associated with clinical 
outcome. In the absence of large randomised controlled 
trials, these findings must be considered in conjunction with 
clinical decision making tailored to each patient.
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